Amgen Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 05:00PM GMT
Ying Huang - BofA Merrill Lynch, Research Division - Director in Equity Research

Good morning, everyone. Welcome to Day 2 of the Bank of America Merrill Lynch Global Healthcare Conference. My name is Ying Huang, and I'm senior analyst covering U.S. large cap biotech here at BofA. We're very pleased to introduce our next company, Amgen. Well, the fire's up already. So we're going to use the fireside chat format. We have the EVP and CFO David Meline; and also Arvind Sood, Head of Investor Relations from Amgen with us. So while the fire's up, I guess.

David W. Meline - Amgen Inc. - Executive VP & CFO

Thank you, Ying. Yes. So we always use this for fireside chat. It sort of sets the -- again, the relax mood in the room, calms everybody down right? Yes. So I'll give a few comments of introduction, and then we can go to Q&A.

So I'm David Meline with Amgen. I think those of you who know us recognize that we've established a very good and stable track record of execution over recent years. The first quarter was no exception of that. We had mid-single

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot